About
Dr. Hakimeh Ebrahimi-Nik is a tumor immunologist. She has clarified the mechanisms of adjuvanticity of DCs in cancer immunotherapy field. She also developed unique research into neoepitope based cancer immunotherapy that resulted in finding new rules of neoepitopes selection for cancer patients. Her recent publication in Nature focused on the mechanism of action of a novel immunotherapy drug AC484, which is now in phase I clinical trial.
Current Position
Currently, she serves as an assistant professor at the Ohio State Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology. She studies the interaction between immune cells and tumor cells with a specific focus on the functional dynamics of CD8 T cells.
Awards & Recognition
- 2025
Young Investigator Travel Award
Society for Immunotherapy of Cancer (SITC)
One of 40 Young Investigator Travel Awards marking the society's 40th anniversary year, presented at SITC 2025 in National Harbor, Maryland.
Research Focus
Dr. Ebrahimi-Nik's research is dedicated to understanding the complex interactions between immune cells and tumor cells, with particular emphasis on the functional dynamics of CD8 T cells that demonstrate tumor-rejecting capabilities. Her work aims to improve our understanding of the immune system's interactions with tumors and to uncover new therapeutic opportunities.